Company Filing History:
1 out of 639 
1 out of 4,555 
Years Active: 2022
Title: Alison Evelynn Ondrus: Innovator in Epstein-Barr Virus Research
Introduction
Alison Evelynn Ondrus is a notable inventor based in Pasadena, CA (US). She has made significant contributions to the field of immunology, particularly in the development of antibodies targeting the Epstein-Barr virus (EBV). Her work has the potential to impact the treatment and prevention of EBV infections and associated diseases.
Latest Patents
Alison Ondrus holds a patent for "Epstein-Barr virus antibodies and uses thereof." This patent discloses antibodies or immunogenic fragments that specifically bind to EBV glycoprotein 350 (gp350) or 220, neutralizing EBV infection. The patent also includes immunogenic peptides comprising gp350 epitopes, EBV antibody-small molecule conjugates, and pharmaceutical compositions that can be used to treat or prevent EBV infections and related conditions.
Career Highlights
Throughout her career, Alison has worked with esteemed organizations such as City of Hope and the California Institute of Technology. Her research has focused on developing innovative solutions to combat viral infections, showcasing her dedication to advancing medical science.
Collaborations
Alison has collaborated with notable colleagues, including Javier Gordon Ogembo and Lorraine Zvichapera Mutsvunguma. These partnerships have contributed to her research and the development of her patented technologies.
Conclusion
Alison Evelynn Ondrus is a pioneering inventor whose work on Epstein-Barr virus antibodies represents a significant advancement in the field of immunology. Her contributions have the potential to improve treatment options for patients affected by EBV infections.